Global Blood Therapeutics (Global Blood Therapeutics) EPS (Basic) : $-5.01 (TTM As of Jun. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics EPS (Basic)?

Global Blood Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Jun. 2022 was $-1.26. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2022 was $-5.01.

Global Blood Therapeutics's EPS (Diluted) for the three months ended in Jun. 2022 was $-1.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-5.01.

Global Blood Therapeutics's EPS without NRI for the three months ended in Jun. 2022 was $-1.26. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2022 was -5.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Global Blood Therapeutics EPS (Basic) Historical Data

The historical data trend for Global Blood Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Blood Therapeutics EPS (Basic) Chart

Global Blood Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EPS (Basic)

Get a 7-Day Free Trial

-2.76

-3.41

-4.57

-4.04

-4.81

Global Blood Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EPS (Basic)	Get a 7-Day Free Trial															-1.12	-1.13	-1.36	-1.26	-1.26

Global Blood Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Global Blood Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-303.091	-	0)	/	62.963
	=	-4.81

Global Blood Therapeutics's Basic EPS for the quarter that ended in Jun. 2022 is calculated as

Basic EPS (Q: Jun. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-82.47	-	0)	/	65.595
	=	-1.26

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.01

Global Blood Therapeutics (NAS:GBT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Global Blood Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.gbt.com

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Executives

Jeffrey S Farrow	officer: Chief Financial Officer	TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo	director	ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik	officer: Chief Human Resources Officer	6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink	officer: Chief Human Resources Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers	officer: Chief Scientific Officer	C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun	officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry	director	176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love	director, officer: See Remarks	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari	officer: Chief Legal Officer	3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr.	director	C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080